{"gene":"TG_251540","gene_symbol":"GRA9","run_date":"2026-09-08T12:58:25","timeline":{"discoveries":[{"year":2004,"finding":"GRA9 is a dense granule protein (318 aa, 41 kDa) that, after secretion from the anterior end of the parasite, associates with the intravacuolar network (IVN) of tubular membranes within the parasitophorous vacuole. Unlike GRA2 or GRA6, GRA9 does not transit through the posterior invaginated pocket where the IVN first assembles. Within dense granules GRA9 exists in both soluble and insoluble states, but is secreted only as a soluble form; inside the vacuolar space two forms are detected: a soluble form and a membrane-associated form. The dual properties are attributed to amphipathic and hydrophobic alpha-helices despite the protein being predominantly hydrophilic.","method":"Immunofluorescence microscopy and cryo-electron microscopy; subcellular fractionation / Western blot","journal":"International journal for parasitology","confidence":"High","confidence_rationale":"Tier 2 / Strong — two orthogonal direct imaging methods (IFA + cryo-EM) combined with biochemical fractionation, single lab but multiple complementary approaches","pmids":["15491588"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2013,"finding":"GRA9 physically associates with bradyzoite pseudokinase 1 (BPK1), a cyst wall component, as identified by immunoprecipitation from in vitro bradyzoite cultures. GRA9 was co-precipitated along with MAG1, MCP4, and GRA8.","method":"Immunoprecipitation (Co-IP) from bradyzoite cultures followed by protein identification","journal":"Eukaryotic cell","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — single Co-IP experiment, single lab, no reciprocal pull-down reported","pmids":["23291621"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2019,"finding":"Genetic deletion of gra9 (IVN membrane-associated GRA) in the type II Pru strain caused severe defects in chronic-stage cyst development in vivo without affecting parasite growth rate or in vitro differentiation into cysts, placing GRA9 as required for successful chronic infection.","method":"Gene deletion (knockout) in type II Prugniaud strain; in vivo mouse infection assay; in vitro cyst formation assay","journal":"mBio","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with defined in vivo phenotype replicated across multiple IVN-GRA deletions and corroborated by independent study (PMID:31619500)","pmids":["31266861"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":"Prugniaud (Pru)"}]},{"year":2019,"finding":"During cyst development in vitro, GRA9 dynamically redistributes: by day 1 post-differentiation GRA9 colocalizes with Dolichos biflorus agglutinin stain at the cyst periphery; by day 2 it establishes a continuous matrix pattern inside the cyst; and GRA9 localizes predominantly in the inner layers of the cyst wall. Deletion of gra9 reduces the rate of accumulation of cyst wall proteins at the cyst periphery relative to the cyst interior.","method":"Immunofluorescence microscopy (co-localization with cyst-wall markers, DBA staining) of knockout and wild-type parasites during in vitro differentiation","journal":"mSphere","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct live-imaging localization time-course combined with genetic knockout phenotype, corroborated by parallel work (PMID:31266861)","pmids":["31619500"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":"Prugniaud (Pru)"}]},{"year":2019,"finding":"Knockout of GRA9 in the type II PLK strain (PLKΔGRA9) inhibited plaque formation and parasite egress from the parasitophorous vacuole, and significantly reduced virulence in mice. These phenotypes were rescued by complementation with a synonymous PLK gra9 allele. In contrast, RHΔGRA9 (type I) showed no difference in plaque formation or egress but had a defect in host cell invasion, indicating strain-specific roles for GRA9.","method":"CRISPR/Cas9 knockout; complementation; plaque assay; egress assay; in vivo mouse virulence assay (BALB/c mice)","journal":"Molecular and biochemical parasitology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR knockout with genetic complementation rescue in two strains, multiple phenotypic assays, single lab","pmids":["30849416"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":"PLK"},{"species":"Toxoplasma gondii","strain":"RH"}]},{"year":2020,"finding":"GRA9 interacts with NLRP3 (NLR family pyrin domain-containing 3) in host macrophages. The C-terminal domain of GRA9 (GRA9C) is essential for this interaction and disrupts NLRP3 inflammasome assembly by blocking the binding of ASC to NLRP3. Residue Q200 within GRA9C is specifically required for the NLRP3 interaction and blockade of ASC conjugation. Recombinant GRA9C exerted anti-inflammatory effects and promoted M1-to-M2 macrophage conversion in vitro and reduced sepsis pathology in vivo.","method":"Co-immunoprecipitation / interaction assay; site-directed mutagenesis (Q200); recombinant protein treatment of macrophages; CLP- and bacterial-induced sepsis mouse model","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus mutagenesis identifying key residue, functional rescue with recombinant protein, but single lab and abstract does not detail reciprocal pull-down","pmids":["33182702"],"is_preprint":false,"attribution":[{"species":"Toxoplasma gondii","strain":""}]}],"current_model":"GRA9 is a dense granule protein that is secreted as a soluble form and associates with the intravacuolar network (IVN) tubular membranes of the parasitophorous vacuole via amphipathic/hydrophobic helices; it dynamically redistributes to the cyst wall during bradyzoite differentiation, where it promotes cyst wall maturation and is required for efficient chronic infection in vivo, for parasite egress from the PV, and for virulence in a strain-specific (type II > type I) manner; additionally, through its C-terminal domain (residue Q200), GRA9 interacts with host NLRP3 to block ASC–NLRP3 binding and suppress inflammasome activation in host macrophages."},"narrative":{"mechanistic_narrative":"GRA9 is a Toxoplasma gondii dense granule protein that shapes the parasitophorous vacuole and cyst-wall environment and modulates host immunity during infection [PMID:15491588, PMID:31266861]. After secretion from the anterior end of the parasite, GRA9 associates with the intravacuolar network (IVN) of tubular membranes, existing in both soluble and membrane-associated forms; its amphipathic and hydrophobic alpha-helices account for these dual solubility properties despite an overall hydrophilic character [PMID:15491588]. During bradyzoite differentiation GRA9 dynamically redistributes to the cyst periphery and then into the inner layers of the maturing cyst wall, where it associates with cyst-wall components including the pseudokinase BPK1, and its loss slows the accumulation of cyst-wall proteins at the periphery [PMID:23291621, PMID:31619500]. Consistent with this role, deletion of gra9 in type II strains causes severe chronic-stage cyst defects in vivo and impairs plaque formation, egress from the vacuole, and virulence, whereas the type I RH knockout instead shows an invasion defect, defining a strain-specific requirement [PMID:31266861, PMID:30849416]. Beyond the parasite, the GRA9 C-terminal domain binds host NLRP3 through residue Q200 and blocks ASC recruitment to NLRP3, suppressing inflammasome assembly and promoting an anti-inflammatory M2 macrophage state [PMID:33182702].","teleology":[{"year":2004,"claim":"Establishing where GRA9 goes after secretion clarified how a dense granule protein contributes to vacuole architecture, showing it targets the IVN tubular membranes by a route distinct from GRA2/GRA6.","evidence":"IFA, cryo-EM, and subcellular fractionation/Western blot in T. gondii","pmids":["15491588"],"confidence":"High","gaps":["Molecular determinants of IVN targeting not mapped to specific residues","Function of the membrane association at the IVN not defined","No genetic loss-of-function to link localization to a phenotype"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2013,"claim":"Identifying GRA9 in a cyst-wall protein complex linked the dense granule protein to bradyzoite-stage structures, implicating it in cyst-wall biology beyond the acute vacuole.","evidence":"Co-IP from in vitro bradyzoite cultures with protein identification (co-precipitated with BPK1, MAG1, MCP4, GRA8)","pmids":["23291621"],"confidence":"Medium","gaps":["Single Co-IP without reciprocal pull-down","Direct vs indirect association with BPK1 unresolved","Functional consequence of the interaction untested"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":2019,"claim":"Genetic deletion tied GRA9 to chronic infection, showing it is dispensable for growth and in vitro differentiation but required for successful cyst development in vivo.","evidence":"gra9 knockout in type II Pru strain with in vivo mouse infection and in vitro cyst assays","pmids":["31266861"],"confidence":"High","gaps":["Mechanism connecting IVN association to chronic-stage phenotype unclear","Whether defect reflects cyst-wall integrity or another process not resolved"],"attribution":[{"species":"Toxoplasma gondii","strain":"Prugniaud (Pru)"}]},{"year":2019,"claim":"Time-resolved imaging of differentiating parasites showed GRA9 redistributes into the inner cyst wall and that its loss slows cyst-wall protein accumulation, defining a role in cyst-wall maturation.","evidence":"IFA co-localization time-course with DBA and cyst-wall markers in wild-type and knockout parasites during in vitro differentiation","pmids":["31619500"],"confidence":"High","gaps":["How GRA9 promotes cyst-wall protein deposition mechanistically unknown","Interaction network at the cyst wall not fully defined"],"attribution":[{"species":"Toxoplasma gondii","strain":"Prugniaud (Pru)"}]},{"year":2019,"claim":"Comparing knockouts across strains revealed GRA9 functions are strain-specific, with type II requiring GRA9 for egress and virulence and type I RH requiring it for invasion.","evidence":"CRISPR/Cas9 knockout with complementation rescue, plaque, egress, and mouse virulence assays in PLK and RH strains","pmids":["30849416"],"confidence":"High","gaps":["Molecular basis of the type-I invasion vs type-II egress divergence unknown","Whether allelic sequence differences drive the strain specificity untested"],"attribution":[{"species":"Toxoplasma gondii","strain":"PLK"},{"species":"Toxoplasma gondii","strain":"RH"}]},{"year":2020,"claim":"Mapping a host-directed activity showed GRA9's C-terminal domain binds NLRP3 to block inflammasome assembly, defining a mechanism for parasite suppression of host inflammation.","evidence":"Co-IP, Q200 site-directed mutagenesis, recombinant GRA9C treatment of macrophages, and CLP/bacterial sepsis mouse models","pmids":["33182702"],"confidence":"Medium","gaps":["Reciprocal pull-down not detailed","Whether native secreted GRA9 reaches host cytosolic NLRP3 during infection not demonstrated","Relationship between the host-immune role and the cyst-wall/vacuolar roles unresolved"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]},{"year":null,"claim":"How GRA9's IVN membrane association, cyst-wall maturation function, strain-specific egress/invasion roles, and host NLRP3 modulation are mechanistically integrated remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking the amphipathic helices to membrane/protein interactions","Domain requirements for each distinct function not systematically mapped","Whether one GRA9 activity underlies the others is unknown"],"attribution":[{"species":"Toxoplasma gondii","strain":""}]}],"mechanism_profile":{"molecular_activity":[],"localization":[],"pathway":[],"complexes":["Cyst-wall protein complex (GRA9 co-precipitates with BPK1, MAG1, MCP4, GRA8)"],"partners":["BPK1","MAG1","MCP4","GRA8","HOST NLRP3"],"other_free_text":["Secreted as a soluble form from the anterior end and exists in soluble and membrane-associated forms within the vacuole; dual behavior attributed to amphipathic and hydrophobic alpha-helices [#0].","Redistributes from cyst periphery to inner cyst-wall layers during bradyzoite differentiation and promotes cyst-wall protein accumulation [#3].","Type II GRA9 is required for egress from the vacuole and virulence; type I RH GRA9 is instead required for host cell invasion [#4].","GRA9 C-terminal residue Q200 mediates NLRP3 binding and blockade of ASC recruitment; recombinant GRA9C drives M1-to-M2 macrophage conversion and reduces sepsis pathology [#5]."]},"strain_conflicts":[{"aspect":"Loss-of-function phenotype of GRA9 knockout across T. gondii strains","claims":[{"attribution":[{"species":"Toxoplasma gondii","strain":"PLK"}],"claim":"Type II PLKΔGRA9 shows inhibited plaque formation, defective egress from the vacuole, and reduced virulence, rescued by complementation.","supporting_discovery_ids":[4]},{"attribution":[{"species":"Toxoplasma gondii","strain":"RH"}],"claim":"Type I RHΔGRA9 shows no defect in plaque formation or egress but a defect in host cell invasion.","supporting_discovery_ids":[4]}]}]},"prefetch_data":{},"corpus_meta":[{"pmid":"31266861","id":"PMC_31266861","title":"Toxoplasma gondii Parasitophorous Vacuole Membrane-Associated Dense Granule Proteins Orchestrate Chronic Infection and GRA12 Underpins Resistance to Host Gamma Interferon.","date":"2019","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/31266861","citation_count":75,"is_preprint":false},{"pmid":"15491588","id":"PMC_15491588","title":"GRA9, a new Toxoplasma gondii dense granule protein associated with the intravacuolar network of tubular membranes.","date":"2004","source":"International journal for parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/15491588","citation_count":41,"is_preprint":false},{"pmid":"23291621","id":"PMC_23291621","title":"Bradyzoite pseudokinase 1 is crucial for efficient oral infectivity of the Toxoplasma gondii tissue cyst.","date":"2013","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/23291621","citation_count":41,"is_preprint":false},{"pmid":"31619500","id":"PMC_31619500","title":"Toxoplasma gondii Intravacuolar-Network-Associated Dense Granule Proteins Regulate Maturation of the Cyst Matrix and Cyst Wall.","date":"2019","source":"mSphere","url":"https://pubmed.ncbi.nlm.nih.gov/31619500","citation_count":29,"is_preprint":false},{"pmid":"25300561","id":"PMC_25300561","title":"The optimal mixture of Toxoplasma gondii recombinant antigens (GRA1, P22, ROP1) for diagnosis of ovine toxoplasmosis.","date":"2014","source":"Veterinary parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/25300561","citation_count":20,"is_preprint":false},{"pmid":"33182702","id":"PMC_33182702","title":"Toxoplasma gondii GRA9 Regulates the Activation of NLRP3 Inflammasome to Exert Anti-Septic Effects in Mice.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33182702","citation_count":19,"is_preprint":false},{"pmid":"33776955","id":"PMC_33776955","title":"PLK:Δgra9 Live Attenuated Strain Induces Protective Immunity Against Acute and Chronic Toxoplasmosis.","date":"2021","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33776955","citation_count":10,"is_preprint":false},{"pmid":"30849416","id":"PMC_30849416","title":"Characterization of strain-specific phenotypes associated with knockout of dense granule protein 9 in Toxoplasma gondii.","date":"2019","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/30849416","citation_count":8,"is_preprint":false},{"pmid":"38673969","id":"PMC_38673969","title":"The Development of Toxoplasma gondii Recombinant Trivalent Chimeric Proteins as an Alternative to Toxoplasma Lysate Antigen (TLA) in Enzyme-Linked Immunosorbent Assay (ELISA) for the Detection of Immunoglobulin G (IgG) in Small Ruminants.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38673969","citation_count":8,"is_preprint":false},{"pmid":"38623843","id":"PMC_38623843","title":"Molecular regulation of NLRP3 inflammasome activation during parasitic infection.","date":"2024","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/38623843","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8465,"output_tokens":2012,"usd":0.027787,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":7304,"output_tokens":3421,"usd":0.061023,"stage2_stop_reason":"end_turn"},"total_usd":0.08881,"stage1_batch_id":"msgbatch_01TEPNZ4MCzJ7xtsNwosiDRk","stage2_batch_id":"msgbatch_01FQShM7n1sfCr4pWTDShmki","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"GRA9 is a dense granule protein (318 aa, 41 kDa) that, after secretion from the anterior end of the parasite, associates with the intravacuolar network (IVN) of tubular membranes within the parasitophorous vacuole. Unlike GRA2 or GRA6, GRA9 does not transit through the posterior invaginated pocket where the IVN first assembles. Within dense granules GRA9 exists in both soluble and insoluble states, but is secreted only as a soluble form; inside the vacuolar space two forms are detected: a soluble form and a membrane-associated form. The dual properties are attributed to amphipathic and hydrophobic alpha-helices despite the protein being predominantly hydrophilic.\",\n      \"method\": \"Immunofluorescence microscopy and cryo-electron microscopy; subcellular fractionation / Western blot\",\n      \"journal\": \"International journal for parasitology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two orthogonal direct imaging methods (IFA + cryo-EM) combined with biochemical fractionation, single lab but multiple complementary approaches\",\n      \"pmids\": [\"15491588\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GRA9 physically associates with bradyzoite pseudokinase 1 (BPK1), a cyst wall component, as identified by immunoprecipitation from in vitro bradyzoite cultures. GRA9 was co-precipitated along with MAG1, MCP4, and GRA8.\",\n      \"method\": \"Immunoprecipitation (Co-IP) from bradyzoite cultures followed by protein identification\",\n      \"journal\": \"Eukaryotic cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP experiment, single lab, no reciprocal pull-down reported\",\n      \"pmids\": [\"23291621\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Genetic deletion of gra9 (IVN membrane-associated GRA) in the type II Pru strain caused severe defects in chronic-stage cyst development in vivo without affecting parasite growth rate or in vitro differentiation into cysts, placing GRA9 as required for successful chronic infection.\",\n      \"method\": \"Gene deletion (knockout) in type II Prugniaud strain; in vivo mouse infection assay; in vitro cyst formation assay\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with defined in vivo phenotype replicated across multiple IVN-GRA deletions and corroborated by independent study (PMID:31619500)\",\n      \"pmids\": [\"31266861\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"Prugniaud (Pru)\"}]\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"During cyst development in vitro, GRA9 dynamically redistributes: by day 1 post-differentiation GRA9 colocalizes with Dolichos biflorus agglutinin stain at the cyst periphery; by day 2 it establishes a continuous matrix pattern inside the cyst; and GRA9 localizes predominantly in the inner layers of the cyst wall. Deletion of gra9 reduces the rate of accumulation of cyst wall proteins at the cyst periphery relative to the cyst interior.\",\n      \"method\": \"Immunofluorescence microscopy (co-localization with cyst-wall markers, DBA staining) of knockout and wild-type parasites during in vitro differentiation\",\n      \"journal\": \"mSphere\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct live-imaging localization time-course combined with genetic knockout phenotype, corroborated by parallel work (PMID:31266861)\",\n      \"pmids\": [\"31619500\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"Prugniaud (Pru)\"}]\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Knockout of GRA9 in the type II PLK strain (PLKΔGRA9) inhibited plaque formation and parasite egress from the parasitophorous vacuole, and significantly reduced virulence in mice. These phenotypes were rescued by complementation with a synonymous PLK gra9 allele. In contrast, RHΔGRA9 (type I) showed no difference in plaque formation or egress but had a defect in host cell invasion, indicating strain-specific roles for GRA9.\",\n      \"method\": \"CRISPR/Cas9 knockout; complementation; plaque assay; egress assay; in vivo mouse virulence assay (BALB/c mice)\",\n      \"journal\": \"Molecular and biochemical parasitology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR knockout with genetic complementation rescue in two strains, multiple phenotypic assays, single lab\",\n      \"pmids\": [\"30849416\"],\n      \"is_preprint\": false,\n      \"attribution\": [\n        {\"species\": \"Toxoplasma gondii\", \"strain\": \"PLK\"},\n        {\"species\": \"Toxoplasma gondii\", \"strain\": \"RH\"}\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GRA9 interacts with NLRP3 (NLR family pyrin domain-containing 3) in host macrophages. The C-terminal domain of GRA9 (GRA9C) is essential for this interaction and disrupts NLRP3 inflammasome assembly by blocking the binding of ASC to NLRP3. Residue Q200 within GRA9C is specifically required for the NLRP3 interaction and blockade of ASC conjugation. Recombinant GRA9C exerted anti-inflammatory effects and promoted M1-to-M2 macrophage conversion in vitro and reduced sepsis pathology in vivo.\",\n      \"method\": \"Co-immunoprecipitation / interaction assay; site-directed mutagenesis (Q200); recombinant protein treatment of macrophages; CLP- and bacterial-induced sepsis mouse model\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus mutagenesis identifying key residue, functional rescue with recombinant protein, but single lab and abstract does not detail reciprocal pull-down\",\n      \"pmids\": [\"33182702\"],\n      \"is_preprint\": false,\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    }\n  ],\n  \"current_model\": \"GRA9 is a dense granule protein that is secreted as a soluble form and associates with the intravacuolar network (IVN) tubular membranes of the parasitophorous vacuole via amphipathic/hydrophobic helices; it dynamically redistributes to the cyst wall during bradyzoite differentiation, where it promotes cyst wall maturation and is required for efficient chronic infection in vivo, for parasite egress from the PV, and for virulence in a strain-specific (type II > type I) manner; additionally, through its C-terminal domain (residue Q200), GRA9 interacts with host NLRP3 to block ASC–NLRP3 binding and suppress inflammasome activation in host macrophages.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GRA9 is a Toxoplasma gondii dense granule protein that shapes the parasitophorous vacuole and cyst-wall environment and modulates host immunity during infection [#0, #2]. After secretion from the anterior end of the parasite, GRA9 associates with the intravacuolar network (IVN) of tubular membranes, existing in both soluble and membrane-associated forms; its amphipathic and hydrophobic alpha-helices account for these dual solubility properties despite an overall hydrophilic character [#0]. During bradyzoite differentiation GRA9 dynamically redistributes to the cyst periphery and then into the inner layers of the maturing cyst wall, where it associates with cyst-wall components including the pseudokinase BPK1, and its loss slows the accumulation of cyst-wall proteins at the periphery [#1, #3]. Consistent with this role, deletion of gra9 in type II strains causes severe chronic-stage cyst defects in vivo and impairs plaque formation, egress from the vacuole, and virulence, whereas the type I RH knockout instead shows an invasion defect, defining a strain-specific requirement [#2, #4]. Beyond the parasite, the GRA9 C-terminal domain binds host NLRP3 through residue Q200 and blocks ASC recruitment to NLRP3, suppressing inflammasome assembly and promoting an anti-inflammatory M2 macrophage state [#5].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing where GRA9 goes after secretion clarified how a dense granule protein contributes to vacuole architecture, showing it targets the IVN tubular membranes by a route distinct from GRA2/GRA6.\",\n      \"evidence\": \"IFA, cryo-EM, and subcellular fractionation/Western blot in T. gondii\",\n      \"pmids\": [\"15491588\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular determinants of IVN targeting not mapped to specific residues\", \"Function of the membrane association at the IVN not defined\", \"No genetic loss-of-function to link localization to a phenotype\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identifying GRA9 in a cyst-wall protein complex linked the dense granule protein to bradyzoite-stage structures, implicating it in cyst-wall biology beyond the acute vacuole.\",\n      \"evidence\": \"Co-IP from in vitro bradyzoite cultures with protein identification (co-precipitated with BPK1, MAG1, MCP4, GRA8)\",\n      \"pmids\": [\"23291621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP without reciprocal pull-down\", \"Direct vs indirect association with BPK1 unresolved\", \"Functional consequence of the interaction untested\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Genetic deletion tied GRA9 to chronic infection, showing it is dispensable for growth and in vitro differentiation but required for successful cyst development in vivo.\",\n      \"evidence\": \"gra9 knockout in type II Pru strain with in vivo mouse infection and in vitro cyst assays\",\n      \"pmids\": [\"31266861\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting IVN association to chronic-stage phenotype unclear\", \"Whether defect reflects cyst-wall integrity or another process not resolved\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"Prugniaud (Pru)\"}]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Time-resolved imaging of differentiating parasites showed GRA9 redistributes into the inner cyst wall and that its loss slows cyst-wall protein accumulation, defining a role in cyst-wall maturation.\",\n      \"evidence\": \"IFA co-localization time-course with DBA and cyst-wall markers in wild-type and knockout parasites during in vitro differentiation\",\n      \"pmids\": [\"31619500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How GRA9 promotes cyst-wall protein deposition mechanistically unknown\", \"Interaction network at the cyst wall not fully defined\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"Prugniaud (Pru)\"}]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Comparing knockouts across strains revealed GRA9 functions are strain-specific, with type II requiring GRA9 for egress and virulence and type I RH requiring it for invasion.\",\n      \"evidence\": \"CRISPR/Cas9 knockout with complementation rescue, plaque, egress, and mouse virulence assays in PLK and RH strains\",\n      \"pmids\": [\"30849416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the type-I invasion vs type-II egress divergence unknown\", \"Whether allelic sequence differences drive the strain specificity untested\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"PLK\"}, {\"species\": \"Toxoplasma gondii\", \"strain\": \"RH\"}]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapping a host-directed activity showed GRA9's C-terminal domain binds NLRP3 to block inflammasome assembly, defining a mechanism for parasite suppression of host inflammation.\",\n      \"evidence\": \"Co-IP, Q200 site-directed mutagenesis, recombinant GRA9C treatment of macrophages, and CLP/bacterial sepsis mouse models\",\n      \"pmids\": [\"33182702\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reciprocal pull-down not detailed\", \"Whether native secreted GRA9 reaches host cytosolic NLRP3 during infection not demonstrated\", \"Relationship between the host-immune role and the cyst-wall/vacuolar roles unresolved\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GRA9's IVN membrane association, cyst-wall maturation function, strain-specific egress/invasion roles, and host NLRP3 modulation are mechanistically integrated remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking the amphipathic helices to membrane/protein interactions\", \"Domain requirements for each distinct function not systematically mapped\", \"Whether one GRA9 activity underlies the others is unknown\"],\n      \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 3], \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]},\n      {\"term_id\": \"GO:0019904\", \"supporting_discovery_ids\": [1, 5], \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0020003\", \"supporting_discovery_ids\": [0], \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]},\n      {\"term_id\": \"GO:0016020\", \"supporting_discovery_ids\": [0], \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0002830\", \"supporting_discovery_ids\": [5], \"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"\"}]}\n    ],\n    \"complexes\": [\"Cyst-wall protein complex (GRA9 co-precipitates with BPK1, MAG1, MCP4, GRA8)\"],\n    \"partners\": [\"BPK1\", \"MAG1\", \"MCP4\", \"GRA8\", \"host NLRP3\"],\n    \"other_free_text\": [\n      \"Secreted as a soluble form from the anterior end and exists in soluble and membrane-associated forms within the vacuole; dual behavior attributed to amphipathic and hydrophobic alpha-helices [#0].\",\n      \"Redistributes from cyst periphery to inner cyst-wall layers during bradyzoite differentiation and promotes cyst-wall protein accumulation [#3].\",\n      \"Type II GRA9 is required for egress from the vacuole and virulence; type I RH GRA9 is instead required for host cell invasion [#4].\",\n      \"GRA9 C-terminal residue Q200 mediates NLRP3 binding and blockade of ASC recruitment; recombinant GRA9C drives M1-to-M2 macrophage conversion and reduces sepsis pathology [#5].\"\n    ]\n  },\n  \"strain_conflicts\": [\n    {\n      \"aspect\": \"Loss-of-function phenotype of GRA9 knockout across T. gondii strains\",\n      \"claims\": [\n        {\"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"PLK\"}], \"claim\": \"Type II PLK\\u0394GRA9 shows inhibited plaque formation, defective egress from the vacuole, and reduced virulence, rescued by complementation.\", \"supporting_discovery_ids\": [4]},\n        {\"attribution\": [{\"species\": \"Toxoplasma gondii\", \"strain\": \"RH\"}], \"claim\": \"Type I RH\\u0394GRA9 shows no defect in plaque formation or egress but a defect in host cell invasion.\", \"supporting_discovery_ids\": [4]}\n      ]\n    }\n  ]\n}","audit_flag":null,"strains":[{"strain":"ME49","gene_id":"TGME49_251540","name":"GRA9","product":"dense granule protein GRA9","uniprot_acc":"A0A125YVM0","chromosome":"TGME49_chrXII","start_pos":5450174},{"strain":"GT1","gene_id":"TGGT1_251540","name":null,"product":"dense granule protein GRA9","uniprot_acc":null,"chromosome":"TGGT1_chrXII","start_pos":5372511},{"strain":"RH88","gene_id":"TGRH88_064400","name":null,"product":"dense granule protein GRA9","uniprot_acc":null,"chromosome":"CM023093","start_pos":5531890},{"strain":"VEG","gene_id":"TGVEG_251540","name":null,"product":"dense granule protein GRA9","uniprot_acc":"B6KHS2","chromosome":"TGVEG_chrXII","start_pos":5441809}]}